COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS

ZHEYING ZHANG1, CHENG FANG2, YONGXIA WANG1, JINGHANG ZHANG3, JIAN YU3, YONGXI ZHANG4, XIANWEI WANG5 and JIATENG ZHONG1,6

1Department of Pathology, Xinxiang Medical University, Xinxiang, Henan 453003; 2Department of Anesthesiology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100; 3Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453003; 4Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100; 5Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, Henan 453003; 6Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine in Henan Province, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China

Received March 13, 2018; Accepted June 8, 2018

DOI: 10.3892/ijo.2018.4536

Abstract. Colorectal cancer (CRC) treatment primarily relies on chemotherapy along with surgery, radiotherapy and, more recently, targeted therapy at the late stages. However, chemotherapeutic drugs have high cytotoxicity, and the similarity between the effects of these drugs on cancerous and healthy cells limits their wider use in clinical settings. Targeted monoclonal antibody treatment may compensate for this deficiency. Epidermal growth factor receptor (EGFR)-targeted drugs have a positive effect on CRC with intact KRAS proto-oncogene GTPase (KRASWT), but may be ineffective or harmful in patients with KRAS mutations (KRASMUT). Therefore, it is important to identify drug target genes that are uniformly effective with regards to KRASWT and KRASMUT CRC. The present study performed gene expression analysis, and identified 294 genes upregulated in KRASWT and KRASMUT CRC samples. Collagen type I α 1 (COL1A1) was identified as the hub gene through STRING and Cytoscape analyses. Consistent with results obtained from Oncomine, a cancer microarray database and web-based data-mining platform, it was demonstrated that the expression of COL1A1 was significantly upregulated in CRC tissues and cell lines regardless of KRAS status. Inhibition of COL1A1 in KRASWT and KRASMUT CRC cell lines significantly decreased cell proliferation and invasion. In addition, increased COL1A1 expression in CRC was significantly associated with serosal invasion, lymph metastases and hematogenous metastases. Taken together, the findings of the present study indicated that COL1A1 may serve as a candidate diagnostic biomarker and a promising therapeutic target for CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer type and the fourth leading cause of cancer-associated mortality worldwide (1). In 2012, there were ~1.36 million cases and 0.7 million mortalities worldwide (2). CRC may be staged according to the American Joint Committee of Cancer tumor node metastasis or Dukes staging system (3,4). Dukes A/B and UICC I/II are considered early-stage CRC, Dukes C/D and UICC III/IV are considered late-stage CRC (5). Surgical removal is the optimal treatment choice for CRC when detected early, but is often diagnosed too late, whereby the only feasible treatment option left is drugs. Cetuximab and bevacizumab exhibit therapeutic effects on CRC, but the treatment mechanisms are different. Cetuximab is an epidermal growth factor receptor (EGFR) monoclonal antibody and bevacizumab is a vascular endothelial growth factor receptor (VEGFR) monoclonal antibody. Clinically, EGFR monoclonal antibodies are considered if the VEGFR expression level of the patient is low. Thus, the present study focused on EGFR-targeted therapy in CRC (6,7). It has been reported that EGFR-targeted drugs exhibit a positive effect on KRAS proto-oncogene GTPase (KRAS) wild-type (KRASWT) CRC, but are ineffective on KRAS mutation (KRASMUT) CRC (8). The Food and Drug Administration (FDA) have approved two monoclonal antibodies (cetuximab and panitumumab) that inhibit EGFR. Cetuximab is a chimeric IgGl anti-EGFR monoclonal antibody, while panitumumab is a complete human IgG2 anti-EGFR
monoclonal antibody (9). Cetuximab and panitumumab have been demonstrated to increase the overall survival rate of CRC; however, cetuximab is <30% effective in patients (10). Clinical data has confirmed that KRAS mutations reduce the effect of cetuximab and panitumumab, resulting in the use of these monoclonal antibodies only in patients with KRAS\textsuperscript{WT} CRC (11). Identifying drugs that are effective on KRAS\textsuperscript{WT} and KRAS\textsuperscript{MUT} CRC has significance for the treatment of patients with advanced CRC.

Bioinformatics is a field of study that uses computational methods to store, retrieve and analyze biological information. It is one of the newest fields of biological research (12). Bioinformatics analysis involves the screening of large datasets from gene chips. There are a number of convenient online analytics tools (GEO2R, GCBI, DAVID, KEGG and GATHER) and analysis software (BRB-ArrayTools and Funrich) available. The present study aimed to investigate the common oncogenes of KRAS\textsuperscript{WT} and KRAS\textsuperscript{MUT} using bioinformatics analysis, and to perform gene function and pathway enrichment analysis. Additionally, the expression of COL1A1 in CRC tissues and cells was verified, and the association between COL1A1 and clinicopathological parameters in CRC clinical samples was analyzed.

KRAS mutation rates reached 40% in patients with CRC, as reported in 2017 (13). Identifying target genes that are effective against wild-type and mutant KRAS may aid in identifying more effective drugs for the treatment of CRC, and provide a theoretical foundation for the application of relevant targets to clinical medicine.

Materials and methods

Microarray data. The gene expression profiles from the GSE38026 dataset were used for analysis in the present study (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38026). GSE38026 was based on the Agilent GPL11532 platform (Affymetrix Human Gene 1.1 ST Array; Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The GSE38026 dataset contained 32 samples, including eight KRAS\textsuperscript{WT}, healthy control colon mucosa samples, eight KRAS\textsuperscript{MUT} healthy control colon mucosa samples, eight KRAS\textsuperscript{WT} CRC samples and eight KRAS\textsuperscript{MUT} CRC samples.

Tissue samples, tissue microarrays and cell lines. A total of 24 pairs of CRC tissues and adjacent non-cancerous controls were collected at Xinxiang Central Hospital (Xinxiang, China) between June 2016 and December 2016. Samples of patients with CRC were all diagnosed as primary CRC for the first time. No patients received radiotherapy, chemotherapy or biological therapy prior to surgery. The patient age range was 33-78 years old, including 9 males and 15 females. The present study was approved by Xinxiang Medical University Ethics Committee, and all patients provided written informed consent for participation in the present study. The tissue specimens were frozen in liquid nitrogen and stored at -80°C. When observed under a microscope, malignant glandular infiltration exceeding mucosal muscularis to the submucosa is considered to indicate colorectal adenocarcinoma, according to the World Health Organization (3). All tissues were confirmed to be adenocarcinoma. Classifications were based on the system of the International Union Against Cancer (3). Tissue chips, including 150 points samples were purchased from Shanghai Outdo Biotech Co., Ltd. (Shanghai, China). The 150 points samples included 75 cancer and 75 healthy tissues. The CRC cell lines LOVO, DLD-1, Caco2, HT29, SW620 and SW480, as well as control intestinal mucosal epithelial FHC cells used in the present study were obtained from the American Type Culture Collection (Manassas, VA, USA) and were cultured in RPMI-1640 (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO\textsubscript{2}. Lovo (KRAS\textsuperscript{MUT}) was derived from a metastatic site of colon adenocarcinoma cells. SW480 (KRAS\textsuperscript{MUT}) was established from a primary adenocarcinoma of the colon. SW620 (KRAS\textsuperscript{MUT}) was derived from a metastasis of the same tumor from which SW480 was derived (12). DLD-1 (KRAS\textsuperscript{MUT}), Caco2 (KRAS\textsuperscript{WT}) and HT29 (KRAS\textsuperscript{WT}) were derived from colorectal adenocarcinoma cell lines (14,15).

Identification of differentially expressed genes (DEGs). Analysis was performed using GEO2R from the National Center for Biotechnology Information (16). DEGs from cancer and adjacent control tissues of KRAS\textsuperscript{WT} and KRAS\textsuperscript{MUT} patients were analyzed. Subsequently, the overlap between the two DEG groups representing similarly behaving genes independent of KRAS status was analyzed. DEGs were selected with a ≥1.2-fold-change and P<0.05 was considered to indicate a statistically significant difference.

Gene ontology (GO) and pathway enrichment analysis of DEGs. GO analysis is used to identify characteristic biological attributes for DEGs, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis may be used to determine which signaling pathways are associated with these DEGs. FunRich is a stand-alone software tool that supports the enrichment analysis for biological processes, cellular components, molecular functions and biological pathways (17). GO enrichment and KEGG pathway analysis were performed using the FunRich tool. P<0.05 was considered to indicate a statistically significant difference.

Integration of the protein-protein interaction (PPI) network and module analysis. STRING (http://www.string-db.org) is a database of known and predicted PPIs. The STRING database (version 10.0) currently covers 9,643,763 proteins from 2,031 organisms (18). DEGs were mapped to STRING to analyze interactive associations among DEGs. An interaction score of >0.4 was considered valid. Subsequently, the network data was exported as simple tabular text and PPIs were constructed using Cytoscape software (19). A plug-in module of MCODE was used to screen for hub proteins (20). MCODE identifies clusters (highly interconnected regions) in a network. The criteria were set as follows: MCODE scores >5 and number of nodes >5.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from tissues and cells using TRIzol reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Total RNA was collected from 24 paired CRC tissues and adjacent
control tissues, and six CRC cell lines (LOVO, DLD-1, Caco2, HT29, SW620 and SW480), as well as control intestinal mucosal epithelial FHC cells. The detailed information of 24 pair samples are presented in Table I. RNA was reverse transcribed to cDNA using a PrimeScript Reverse Transcription kit (Takara Bio, Inc., Otsu, Japan). The RT reaction mixture contained 1 µl RNA (500 ng), 2 µl 5X PrimeScript Buffer, 0.5 µl PrimeScript RT enzyme mix I, 0.5 µl Oligo(dT) primer (50 µM), 0.5 µl random hexamers (100 µM) and 4.5 µl RNase-free ddH2O. The tubes were incubated for 37˚C for 15 min, followed by 85˚C for 5 sec, and then stored at 4˚C in the PCR instrument. qPCR analysis was performed using SYBR-Green I (Takara Bio, Inc.) and each experiment was performed in triplicate. The qPCR reaction mixture contained 10 µl SYBR-Green mix, 0.8 µl forward primer (10 µM), 0.8 µl reverse primer (10 µM), 1 µl cDNA and 7.4 µl RNase/DNase free ddH2O. The mixture was centrifuged (4˚C, 1,000 × g, 10 sec) and then placed in an ABI 7500 fluorescence quantitative PCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). The procedures for the PCR reaction were as follows: Pre-denaturation at 95˚C for 1 min; denaturation at 95˚C for 15 sec; annealing at 60˚C for 15 sec; and extension at 72˚C for 34 sec. Following 40 cycles, the Cq value of each sample was measured. Results were normalized to the expression of GAPDH as previously described (21). The sequences of the COL1A1 primers were as follows: Forward, 5'-GAGGGCCAAGACGAAGACATC-3' and reverse, 5'-CAGATCAGTCATCGCAACAAC-3'. The primers were obtained from PrimerBank (PrimerBank ID 110349771c1), with an amplicon size of 140 bp. The sequences of the GAPDH primers were as follows: Forward, 5'-GACTCATGACCACAGTCATGC-3' and reverse, 5'-AGAGGCAGGGATGATGTTCTG-3'. The 2-ΔΔCq method was used to calculate relative expression levels of COL1A1 in tissues. ΔCq was calculated as Cq(COL1A1)-Cq(GAPDH), and ΔΔCq was calculated as ΔCq(Tumor)-ΔCq(Control). As previously described, GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for graph construction (22).

Tissue microarrays and immunohistochemistry. Tissue microarrays were constructed and immunostaining was performed using a two-step protocol. The tissue microarray was purchased from Shanghai Outdo Biotech Co., Ltd. (catalog no. HCol-Adel50CS-01). Detailed clinicopathological data of the 75 patients is presented in Table II. The two-step immunohistochemical detection kit was purchased from Boster Biological Technology (catalog no. SV0002; Pleasanton, CA, USA). Experimental procedures were performed according to the manufacturer's protocols. COL1A1 expression was measured using the Q550IW Computerized Image system (Leica Microsystems, Ltd., Milton Keynes, UK). The images were viewed using Aperio-ImageScope 12.0 software (23). The anti-human COL1A1 antibody was purchased from Abcam (anti-rabbit; 1:1,000; catalog no. ab34710; Cambridge, MA, USA).
USA). The COL1A1 index was calculated as the (number of COL1A1-positive cells/total number of cells) × 100% (magnification, x200) as previously described (24).

**Immunohistochemistry score.** The total COL1A1 immunostaining score was calculated as the sum of the percentage positivity of stained tumor cells and the staining intensity. The percentage positivity was scored 0-3: 0; <10%; 1, 10-30%; 2, 31-50%; and 3, >50%. The staining intensity was scored 0-3: 0, no staining; 1, weakly stained; 2, moderately stained; and 3, strongly stained. The percentage positivity of cells and staining intensity were decided in a double-blinded manner. Then, the score of COL1A1 expression was calculated as the percentage positivity score × staining intensity score, which ranged between 0 and 9. The final expression level of COL1A1 was defined as ‘low’ (0-4) and ‘high’ (5-9).

**Western blotting.** Total proteins were extracted from CRC cells. The cells were lysed in cold lysis buffer (60 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.25% SDS and 1% Tergitol-type NP-40) containing 10 mM NaF, 1 mM Na<sub>2</sub>VO<sub>4</sub> and complete protease inhibitor (Roche Diagnostics, Basel, Switzerland) for 30 min on ice, and were then centrifuged at 10,000 x g for 15 min as previously described (25). A bicinchoninic acid protein assay was used to determine protein concentration. A total of 45 µg protein was separated on 10% SDS-PAGE, transferred onto nitrocellulose membranes and blocked with 5% skimmed milk. Subsequently, the membranes were incubated with the anti-COL1A1 primary antibody (anti-rabbit; dilution 1:500; catalog no. ab63710) overnight at 4°C. The next day, membranes were incubated with the HRP-conjugated goat anti-rabbit secondary antibody (dilution 1:10,000; catalog no. AS014; ABclonal Biotech Co., Ltd., Woburn, MA, USA) as previously described (26). The percentage positivity was scored 0-3: 0, <10%; 1, 10-30%; 2, 31-50%; and 3, >50%. The staining intensity was scored 0-3: 0, no staining; 1, weakly stained; 2, moderately stained; and 3, strongly stained. The percentage positivity score x staining intensity score, which ranged between 0 and 9. The final expression level of COL1A1 was defined as ‘low’ (0-4) and ‘high’ (5-9).

**Cell invasion assay.** Caco2 and SW480 cells were used for cell invasion assays. A Transwell filter was purchased from Corning Incorporated (Corning, NY, USA). The cells were digested with 0.25% trypsin and seeded into the Transwell upper chamber coated with Matrigel. RPMI-1640 culture medium was added to the upper chamber, while RPMI-1640 with FBS was plated into the lower chamber. After 24 h of culture, the Transwell chamber was removed. Following washing twice with PBS, the cells were fixed with 4% formaldehyde for 20 min at room temperature, washed twice with PBS and stained with Giemsa (10 µg/ml) for 20 min at room temperature. Cells that passed through the Matrigel and the micropores to the lower chamber were observed under a light microscope. Cells were counted under a light microscope (magnification, x200) and the invasion percentage was determined by dividing by the number of cells on the first day as previously described (29).

**Bioinformatics analysis of COL1A1 and NEK2 expression levels.** COL1A1 and NEK2 expression was analyzed in CRC tissues compared with adjacent tissues based on the Oncomine microarray dataset (https://www.oncomine.org/resource/login.html). The genes associated with NEK2 were calculated using GEPIA (http://gepia.cancer-pku.cn/index.html).

**Statistical analysis.** Data were analyzed using SPSS 20.0 statistical software (IBM Corp., Armonk, NY, USA). Quantitative data are presented as the mean ± standard deviation of at least three independent experiments. The differences between multiple groups were assessed using analysis of variance followed by the Tukey's post hoc test, and two groups were examined using a two-tailed Student's t-test. Correlation analysis was determined using Pearson's correlation analysis. The associations between COL1A1 expression and clinicopathological characteristics were determined using the χ<sup>2</sup> test. P<0.05 was considered to indicate a statistically significant difference. P<0.05; P<0.01; P<0.001.

**Results**

**Identification of DEGs common for KRAS<sup>WT</sup> and KRAS<sup>MUT</sup> CRC.** Paired KRAS<sup>WT</sup> cancer samples and adjacent control tissues were analyzed using GEO2R, which led to the identification of 395 upregulated DEGs. Similarly, eight paired KRAS<sup>MUT</sup> cancer samples and adjacent control tissues were analyzed, whereby 519 upregulated DEGs were identified. The intersection of DEGs included 294 common DEGs that were independent of the KRAS genotype (Fig. 1).

**GO and pathway analysis.** Regarding biological processes, upregulated common DEGs exhibited enrichment for cell communication, signal transduction and cell growth (Fig. 2A). Cell component analysis revealed enrichment in cytoplasmic, extracellular and extracellular compartments (Fig. 2B). Regarding molecular function, the DEGs were enriched in metallopeptidase activity, extracellular matrix structural constituents and receptor binding (Fig. 2C). The pathway analysis revealed enhanced involvement in cell cycle, DNA replication and the WNT signaling pathway (Fig. 2D).

**Hub-protein screening from the PPI network.** Based on data from the STRING database, the top three hub modules that satisfied the preset criteria (MCODE score >5 with...
the number of nodes >5), including TPX2 microtubule nucleation factor (TPX2), NIMA related kinase 2 (NEK2) and COL1A1, were identified using Cytoscape software analysis (Fig. 3). The expression levels of COL1A1 were
upregulated 2.1-fold, while NEK2 was increased 1.5-fold in cancer tissues compared to healthy tissues. Drugs targeting NEK2 (Drugbank ID, DB07180; https://www.drugbank.ca/drugs/DB07180) and COL1A1 were identified using Drugbank (Drugbank ID, DB04866; https://www.drugbank.ca/drugs/DB04866), while no drugs targeting TPX2 were identified. Only one type of drug that targets NEK2 was identified and it is in the experimental phase. There are four types of drugs that target COL1A1, but only halofuginone is associated with cancer therapy and is currently in the approval process. Halofuginone is able to inhibit matrix metalloproteinase (MMP) and cell proliferation, as well as inhibit tumor matrix support, vascularization, cell invasion and cell proliferation (30). Therefore, COL1A1 and NEK2 may serve key roles in cancer development, and their target drugs may have important clinical application value.

**COL1A1 mRNA is upregulated in CRC tissues and cells regardless of KRAS genotype.** COL1A1 was identified to be significantly upregulated in CRC tissues compared with adjacent tissues based on the Oncomine microarray dataset, which is a web-based data-mining platform (31) (Fig. 4A). In the Oncomine database, all the CRC chip results were upregulated. Of the 11 upregulated microarray databases, The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/) database was selected to further determine the expression patterns of COL1A1. TCGA is a powerful database platform for integration of multiple cancer genome sequencing data. This database included 19 colon specimens, three rectum specimens and 22 colorectal mucosa adenocarcinoma specimens. The results demonstrated that COL1A1 expression was upregulated 9.62-fold in CRC specimens compared with control colorectal tissue specimens. Additionally, the
expression level of COL1A1 mRNA in tumor and non-tumor tissues from 24 patients with CRC was confirmed. RT-qPCR analysis revealed significantly higher COL1A1 mRNA expression in 20/24 CRC specimens compared with the adjacent control mucosa tissues (P<0.001; Fig. 4B and C). The expression levels of COL1A1 mRNA were further evaluated in six KRAS WT and KRAS MUT CRC cell lines, LOVO, DLD-1, Caco2, HT29, SW620 and SW480. Compared with the control colorectal epithelium FHC cells, the expression levels of COL1A1 mRNA were significantly upregulated in all investigated CRC cell lines (Fig. 4D).

**COL1A1 protein is upregulated in CRC tissues and cells regardless of KRAS genotype.** The protein expression levels of COL1A1 in 75 paired CRC and adjacent control tissues were determined using tissue microarray. COL1A1 protein expression was significantly higher in CRC tissues compared with adjacent tissues (Fig. 5A and B). Furthermore, in order to investigate the clinicopathological significance of COL1A1, the expression of COL1A1 was divided into a high-expression group (n=12) and a low-expression group (n=12) based on the median COL1A1 expression level, which was 5.191489802. It was demonstrated that COL1A1 expression was positively associated with serosal...
ZHANG et al: COL1A1: A POTENTIAL THERAPEUTIC TARGET FOR CRC WITH WILD-TYPE AND MUTANT KRAS

invasion, lymph node metastasis and distant metastasis in CRC, but not with sex, age or tumor size (Table III). The expression of COL1A1 protein was also detected in CRC cell lines. The expression of COL1A1 protein was significantly upregulated in the investigated CRC cell lines compared with that in FHC cells, independent of KRAS status (Fig. 5C and D). These results indicated that the expression of COL1A1 mRNA and protein in CRC cells was increased, regardless of whether KRAS was mutated or not. Therefore, COL1A1 may be effective as a drug target for KRASMU or KRAS\textsuperscript{WT} CRC.

Inhibition of COL1A1 suppresses proliferation and invasion in KRAS\textsuperscript{WT} and KRAS\textsuperscript{MUT} CRC cell lines. Based on the obtained results, two CRC cells lines Caco2 (KRAS\textsuperscript{WT}) and SW480 (KRAS\textsuperscript{MUT}) were selected to explore the role of COL1A1 in cell proliferation and invasion. shRNA COL1A1 was used to inhibit the expression of the COL1A1 in the two cell lines and the efficiency of transfection was assessed by western blotting (Fig. 6A). The cell proliferation assay demonstrated that inhibition of COL1A1 significantly decreased the proliferation of Caco2 and SW480 cells (Fig. 6B and C). Proliferation decreased from the second day and was most notable on the fourth day in the two cell lines. Similarly, inhibition of COL1A1 significantly decreased the invasive abilities of Caco2 and SW480 cells by day 3 (Fig. 6D and E).

Bioinformatics analysis of NEK2 expression level and function. NEK2 was upregulated in CRC tissues compared with adjacent tissues based on the Oncomine microarray dataset. The results of the TCGA database analysis are presented in Fig. 7A. This database included 19 colon specimens, three rectum specimens and 101 colorectal mucosa adenocarcinoma specimens. The results demonstrated that NEK2 expression was upregulated 3.496-fold in CRC specimens compared with control colorectal tissue specimens. Furthermore, the results from the TCGA data revealed that NEK2 was significantly correlated with MYC proto-oncogene bHLH transcription factor (c-Myc), Cyclin D1, cluster of differentiation (CD)44 and Snail genes, but not with MMP9 or MMP2 (Fig. 7B). The data were calculated using GEPIA (http://gepia.cancer-pku.cn/index.html) (Fig. 7). These results suggested that NEK2 may serve a role in tumor proliferation and metastasis, but that it does not promote metastasis by dissolving matrix components.

Discussion

CRC is one of the most common types of malignancies, with >1.2 million patients being diagnosed with CRC and the number of mortalities exceeding 600,000 every year worldwide (32). In the United States and other Western countries, the incidence of colorectal cancer ranks third among all malignant tumors, and the mortality rate in males and in females ranks second and third, respectively (1). Surgical treatment is primarily used at the early stages; however, ~80% of patients are diagnosed with colon cancer at the late stage (2).

The FDA has approved cetuximab and panitumumab for the treatment of advanced CRC. These antibodies target human EGFR (33). Initially, these targeted drugs were used in all patients with CRC, but it was later noted that only KRAS\textsuperscript{WT} patients respond well to treatment, whereas in KRAS\textsuperscript{MUT} patients...
Table III. Clinicopathological characteristics of COL1A1 expression in patients with CRC.

<table>
<thead>
<tr>
<th>Clinicopathological variables</th>
<th>No.</th>
<th>High expression</th>
<th>Low expression</th>
<th>$\chi^2$</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years$^a$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;63</td>
<td>32</td>
<td>16</td>
<td>16</td>
<td>0.010</td>
<td>0.999</td>
</tr>
<tr>
<td>\geq 63</td>
<td>43</td>
<td>22</td>
<td>21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>43</td>
<td>22</td>
<td>21</td>
<td>0.010</td>
<td>0.999</td>
</tr>
<tr>
<td>Female</td>
<td>32</td>
<td>16</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm$^3$)$^b$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;36.5</td>
<td>52</td>
<td>21</td>
<td>29</td>
<td>0.250</td>
<td>0.803</td>
</tr>
<tr>
<td>\geq 36.5</td>
<td>25</td>
<td>9</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serosal invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>61</td>
<td>27</td>
<td>34</td>
<td>5.362</td>
<td>0.036</td>
</tr>
<tr>
<td>No</td>
<td>14</td>
<td>11</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymph metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>39</td>
<td>15</td>
<td>24</td>
<td>4.842</td>
<td>0.038</td>
</tr>
<tr>
<td>No</td>
<td>36</td>
<td>23</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>9</td>
<td>1</td>
<td>8</td>
<td>6.402</td>
<td>0.014</td>
</tr>
<tr>
<td>No</td>
<td>66</td>
<td>37</td>
<td>29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^a$Grouping of age was performed according to median; $^b$tumor size was grouped according to median. Associations between COL1A1 expression and clinicopathological characteristics were determined using the $\chi^2$ test. COL1A1, collagen type I $\alpha$ 1.
the application of antibodies may be not only ineffective, but also harmful (7). Since the proportion of KRAS\textsuperscript{MUT} patients is \~40\% (34), it is important to explore novel drug targets for CRC.

In order to identify drugs targeting genes that are uniformly effective in KRAS\textsuperscript{NT} and KRAS\textsuperscript{MUT} CRC, bioinformatics techniques were used to analyze CRC samples from the GSE38026 gene expression dataset. A total of 294 commonly upregulated genes outside of the KRAS pathway were identified in the present study. These genes serve as a pool of potential uniformly effective therapy targets for CRC.

The results of GO and KEGG analyses demonstrated that the DEGs were enriched for genes involved in cell proliferation, signal transduction and tumor pathways. The PPI network analysis identified three core genes; TPX2, NEK2 and COL1A1. The expression levels of COL1A1 and NEK2 in CRC tissues were upregulated by 2.1- and 1.5-fold compared with healthy tissues, respectively. Drugbank was also searched, and drugs specifically targeting NEK2 and COL1A1 were identified (35). The one drug targeting NEK2 is 5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide. This drug is currently being investigated; thus, its pharmacological effect remains unclear. There are four drugs targeting COL1A1, only the role of halofuginone has been associated with cancer treatment, and is currently in the approval process (36). Halofuginone is an effective inhibitor of COL1A1 and MMP2 gene expression, and inhibits extracellular matrix deposition and cell proliferation (36). The profound antitumor effects of
The present study was supported by the Xinxiang Medical College research funding (grant nos. XYBSKYZZ201632 and 505079), Higher Education Institutions of Henan Province, China (grant no. 17A310023), The National Natural Science Foundation of China (grant no. 81702891), and Taihang Young Scholar Foundation of Xinxiang Medical University and Science and Technology Department of Henan Province, China (grant nos. 172102310651 and 122102310194).

Acknowledgements

Not applicable.

Funding

The present study was supported by the Xinxiang Medical College research funding (grant nos. XYBSKYZZ201632 and 505079), Higher Education Institutions of Henan Province, China (grant no. 17A310023), The National Natural Science Foundation of China (grant no. 81702891), and Taihang Young Scholar Foundation of Xinxiang Medical University and Science and Technology Department of Henan Province, China (grant nos. 172102310651 and 122102310194).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

J ZHONG and XW designed the experiments. ZZ, YW, JL, J ZHANG, CF, YZ and JY performed the experiments and analyzed the data. J ZHONG wrote the manuscript. XW revised the manuscript. All of the authors contributed to the manuscript.

Ethics approval and consent to participate

The present study was approved by Xinxiang Medical University Ethics Committee, and all patients provided written informed consent for participation in the present study.

Competing interests

The authors declare that there are no competing interests.

References

Inhibition of KRAS codon 12 mutants using a novel -


promotes metastasis in colorectal cancer by regulating the


Zhai F, Song N, Ma J, Gong W, Tian H, Li X, Jiang C and Wang H:


interacts with hnRNP-K and activates the WNT/


139-147, 2016.

Qasim BJ, Al-Wasiti EA and Azzal HS: Association of global

Mansour RN, Enderami SE, Ardeshirylajimi A, Fooladsaz K,

hippo pathway in colorectal cancer. Saudi J Gastroenterol 20:

Liang K, Zhou G, Zhang Q, Li J and Zhang C: Expression of


Song E, Song W, Ren M, Xing L, Ni W, Li Y, Gong M, Zhao M,

network structure and improving predictions using EnsembleFBA.

Biggs MB and Papin JA: Managing uncertainty in metabolic

network framework and improving predictions using ensembleFBA.


Mo CH, Gao L, Zhu XF, Wei KL, Zeng JJ, Chen G and Feng ZB:


